ClearPoint Neuro (CLPT) vs Profound Medical (PROF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Profound Medical (PROF) has outperformed ClearPoint Neuro (CLPT) over the past year, gaining 6.2% versus a loss of 50.0%. Over five years, PROF leads with a -43.6% price change compared with -50.0% for CLPT. Profound Medical is the larger company by market cap ($233.7 million vs $221.5 million), about 1.1 times the size.
ClearPoint Neuro converts more of its revenue into profit, with a net margin of -69.1% versus -264.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLPT | PROF |
|---|---|---|
| Share price | $6.91 | $6.38 |
| Market cap | $221.49M | $233.68M |
| 1-day change | -5.47% | -3.19% |
| YTD return | -49.49% | -18.93% |
| 1-year return | -50.00% | +6.16% |
| 5-year return | -50.04% | -43.64% |
| EPS (TTM) | $-1.21 | $-0.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $36.97M | $16.10M |
| Revenue growth (YoY) | +17.78% | +50.73% |
| Net income (latest FY) | $-25.54M | $-42.57M |
| Gross margin | 61.38% | 70.77% |
| Operating margin | -65.36% | -256.27% |
| Net margin | -69.08% | -264.44% |
| 52-week high | $19.63 | $8.95 |
| 52-week low | $6.85 | $4.80 |
| Distance from 52-week high | -64.80% | -28.72% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +211.14% | +74.61% |
| Average volume | 701.64K | 208.29K |
| Shares outstanding | 32.05M | 36.63M |
| Employees | 172 | 162 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PROF has outperformed CLPT by 56.2 percentage points over the past year.
- ClearPoint Neuro is more profitable, keeping -69.1 cents of every revenue dollar as net income versus -264.4 cents for Profound Medical.
- Profound Medical grew revenue faster in its latest fiscal year (+50.73% vs +17.78%).
About ClearPoint Neuro
CLPT stock →ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
Health Care · Medical/Dental Instruments · 172 employees
About Profound Medical
PROF stock →Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.
Health Care · Medical/Dental Instruments · 162 employees
CLPT vs PROF FAQ
Which is bigger, ClearPoint Neuro or Profound Medical?
Profound Medical (PROF) is larger, with a market capitalization of $233.68M compared with $221.49M for ClearPoint Neuro (CLPT).
Which stock has performed better over the past year, CLPT or PROF?
PROF returned +6.16% over the past 12 months, compared with -50.00% for CLPT (price return, excluding dividends). Past performance does not predict future results.
Are ClearPoint Neuro and Profound Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.